Mark Mossler - 18 Sep 2023 Form 3 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Accounting Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
18 Sep 2023
Net transactions value
$0
Form type
3
Filing time
19 Sep 2023, 19:20:38 UTC
Next filing
10 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CCCC Stock Option (Right to Buy) 18 Sep 2023 Common Stock 50,210 $2.83 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on June 21, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney